Integrated PK/PD Modeling for Uliledlimab, an Anti-CD73 Monoclonal Antibody, in Non-Small Cell Lung Cancer Patients Download “Poster presentation at the WCLC 2024” PDF
Uliledlimab and toripalimab combination therapy in treatment-naïve advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker Download "Poster presentation at the 2023 ASCO meeting" PDF
Revealing Novel Immune Modulatory Mechanism of Uliledlimab through the Blockade of CD73 Pathway Download "Poster presentation at the 2022 SITC Meeting" PDF
The safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab, a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer Download "Poster presentation at the 2021 ASCO meeting" PDF
Optimal dose estimation using an integrated approach from Phase I data of givastomig, a novel Claudin18.2×4-1BB bispecific antibody Download “Poster presentation at the 2024 SITC meeting” PDF
Updated Safety and Efficacy from the Phase I Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC) Download “Poster presentation at the 2024 ESMO meeting” PDF
Givastomig, a novel Claudin18.2/4-1BB bispecific antibody, exerts bystander tumor-killing and synergistic anti-tumor activity with therapeutics in 1L/2L treatment for gastric cancer Download "Poster presentation at the 2023 SITC meeting" PDF
First-In-Human Phase I Study of Givastomig, A Novel Claudin 18.2/4-1BB Bispecific Antibody in Advanced Solid Tumors Download "Poster presentation at the 2023 ESMO meeting" PDF
CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation Download JITC Article
TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies Download "Poster presentation at the 2021 SITC meeting" PDF
Claudin 18.2 – 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation Download "Poster presentation at the 2020 AACR meeting" PDF
Phase 1 Trial Safety and Efficacy of Ragistomig, a Bispecific Antibody Targeting PD-L1 and 4-1BB in Advanced Solid Tumors Download "Poster presentation at the 2024 ASCO meeting" PDF
Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade Download JITC Article
ABL503 (TJ-L14B), PD-L1×4–1BB bispecific antibody, reinvigorates exhausted tumor-infiltrating CD8+ T cells and synergizes with PD-1 blockade Download "Poster presentation at the 2023 SITC meeting" PDF
